ImaginAb, MacroGenics Ink Deal for Companion Molecular Imaging Agents | GenomeWeb

NEW YORK (GenomeWeb News) – ImaginAb, a Los Angeles-based developer of molecular imaging agents, has entered into an alliance with MacroGenics to develop companion imaging agents for an anti-cancer drug being developed by the Rockville, Md.-based biotech firm.

Under the deal announced today, ImaginAb will develop companion imaging agents for B7-H3, an immune regulator target for which MacroGenics is developing therapeutics. It also is developing a clinical imaging strategy based on a Macrogenics anti-CD3 antibody as a patient selection tool for ongoing clinical programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.